event-trade登录编辑
ReutersCodex · 实盘不做把握 5/10
北京时间·🕒 发布 06:13:01时区推断·⟳ 抓取 06:13:30·⚡ 决策 07-14 15:10:04 +8h56m·105.2 天前

华盛顿州继续审理Albertsons阿片诉讼,金额未定且属已知法律风险

华盛顿州诉讼进入审理阶段,但公司4月已公告7.74亿美元全国阿片和解,阿片诉讼风险并非新出现。

📄 原文Reuters↗ 原文
Washington state accused Albertsons at a trial that kicked off on Monday of helping ​fuel the opioid epidemic by floodi…
不做 Albertsons(ACI.US)
方向偏负面但索赔金额未定,且7.74亿美元阿片和解为4月旧风险;当前不满足明确强空催化和可借券确认,可考虑降低相关已有多头敞口/等待判赔金额。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

🔎 新鲜度:最早出现 2026-07-13 · 扩散 medium · price-in 风险 medium ↗ ↗ ↗

消息传播链

  1. 2026-04-14官方确认/否认Albertsons/媒体报道非一手原文 ↗
    Albertsons同意以约7.74亿美元解决大量全国阿片相关诉讼,法律风险已被市场提前消化一部分。
  2. 2026-07-13财经媒体扩散Reuters非一手原文 ↗
    华盛顿州诉Albertsons案开庭,州方未说明索赔金额,审理预计持续至9月。
    市场反应:ACI.US最新14.79美元,较前收仅涨0.20%,未见明显负面定价。
  3. 2026-07-13行业媒体转载Supermarket News非一手原文 ↗
    行业媒体同步报道诉讼开庭,强调州方指控药房未能防止药物滥用。

关键理由

  • 华盛顿州诉讼进入审理阶段,但公司4月已公告7.74亿美元全国阿片和解,阿片诉讼风险并非新出现。
  • 华盛顿未披露索赔金额,无法估算相对Albertsons约72.44亿美元市值的新增负债量级。

主要风险

  • 若华盛顿单独判赔显著高于公司已计提或市场预期,可能形成新的负面重定价。

反向证据

  • 做空前查反向 · 来源 web · 日期 2026-04-14 · 影响 weakens
    公司已就大量阿片索赔达成全国和解且否认责任,华盛顿案金额未定,当前缺少强空催化。
    检索:Albertsons opioid settlement 774 million April 2026 adjusted earnings guidance 原文 ↗
  • 做空前查反向 · 来源 stock_quote · 日期 2026-07-14 · 影响 weakens
    报价显示ACI.US当日微涨0.20%,未出现明确负面市场确认;工具未给出可借券数据,不能满足做空红线。
    检索:ACI.US stock_quote full borrow litigation reaction
工具调用 · 历史记录,结果未知(1 种)
  • stock_quote · 结果未知

原文全文

展开原文 · 3,092 字
Washington state accused Albertsons at a trial that kicked off on Monday of helping ​fuel the opioid epidemic by flooding its communities with addictive painkillers and failing to prevent their misuse ‌and diversion.

Jeff Gaddy, an attorney representing the state, said in opening statements that Albertsons, one of the largest U.S. grocery retailers, put profits over safety, and overworked its own pharmacists to the point that they were “defenseless” to investigate potential “red flags” in the prescriptions they filled.

The state in ​2022 sued Albertsons in state court in Seattle, seeking to force it to pay the costs of addressing opioid-related ​harms in the state. Washington did not say how much money it is seeking from ⁠Albertsons in damages, saying that it will address costs and penalties at the end of the trial.

The company, which faced ​thousands of similar legal claims from state and local governments, announced a $774 million nationwide opioid settlement in April, but Washington chose ​to continue its lawsuit rather than joining that deal.

“[Albertsons] fostered a work environment from top to bottom that was chaotic, stressful, and hostile, and where folks felt like they were grinded down to a nub,” Gaddy said on Monday. “Albertsons substantially contributed to the opioid epidemic here within ​the state, and it needs to be cleaned up.”

More than 26,000 state residents have died from an opioid overdose since ​the start of the crisis, and over 7,400 have died in the past three years alone, according to a statement by Washington Attorney ‌General Nick ⁠Brown.

Albertsons operates 200 pharmacies in Washington, mostly under its Safeway brand.

Enu Mainigi, an attorney for the company, said the company sold legal drugs that were prescribed by doctors, and that it would be unfair to blame pharmacists for a change in doctors' prescribing habits.

“The pharmacist's role is not to reexamine patients and question the judgment call of a patient's doctor unless there's ​a real reason to believe ​a prescription is illegitimate,” Mainigi ⁠said.

The trial, which is being overseen by Judge Janet Helson, is expected to last until September.

Albertsons said in a statement that it has strong pharmacy practices that are designed to ​promote safe and responsible use of prescription medicines and that its April settlement is not ​an admission of ⁠liability or wrongdoing.

Washington has actively litigated against drugmakers, pharmacy chains and drug distributors it has accused of fueling the opioid crisis in recent years, often continuing to press its case in court after other states settle their claims.

The state reached a $518 million settlement ⁠after starting ​a trial against three large opioid distributors in 2022, taking about $100 million ​more than it would have received if it had chosen to participate in the nationwide settlement framework proposed by those companies.

Nationwide litigation against opioid companies has ​resulted in more than $50 billion in total settlements , with most of the money going to state and local governments.

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。